Home > > Global Oncology NGS Market Report
The Oncology NGS market was valued at $1,463.1 Million in 2022, and is projected to reach $3,105.1 Million by 2032 growing at a CAGR of 7.88% from 2023 to 2032.The next-generation sequencing (NGS) market in oncology is driven by several factors, including the increasing prevalence of cancer, the development of personalized medicine and targeted therapies, and the growing demand for non-invasive diagnostic tests. There are several companies that are at the forefront of the oncology NGS market, including: Illumina: Illumina is a leading provider of NGS platforms and services for cancer research and diagnostics. The company's product portfolio includes the NovaSeq, HiSeq, and MiSeq platforms, which are widely used in oncology applications. Thermo Fisher Scientific: Thermo Fisher is a global leader in the NGS market, with a strong presence in oncology. The company offers a range of NGS products, including the Ion Torrent platform, which is used for the analysis of cancer-related genes. Roche: Roche is a multinational pharmaceutical company that also offers NGS solutions for cancer research and diagnosis. The company's NGS portfolio includes the 454, Ion Proton, and HiSeq platforms. Agilent Technologies: Agilent Technologies is a leading provider of NGS solutions for cancer research and diagnostics. The company offers a range of NGS products, including the SureSelect, HaloPlex, and SureCall platforms. In terms of recent developments, Illumina has recently launched the NovaSeq 6000Dx system, which is specifically designed for the analysis of liquid biopsy samples in oncology applications. Thermo Fisher Scientific has also launched the Ion S5 Next Generation Sequencing System, which is a high-throughput NGS platform that is well-suited for oncology applications.